

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/T5A19841EF9EN.html>

Date: May 2018

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: T5A19841EF9EN

Abstracts

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2018

SUMMARY

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Cluster of Differentiation 86 or CD86 or B7-2 is a protein expressed on antigen-presenting cells. It plays a critical role in the early events of T-cell activation and co stimulation of naive T-cells, such as deciding between immunity and energy.

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively.

Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Dermatology, Genito Urinary System And Sex Hormones, Oncology, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Alopecia, Autoimmune Disorders, Dermatomyositis, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis

(Scleroderma), Transplant Rejection, Uveitis and Vitiligo.

The latest report T Lymphocyte Activation Antigen CD86 - Pipeline Review, H1 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86)

The report reviews T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86)

targeted therapeutics and enlists all their major and minor projects

The report assesses T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Overview

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Companies Involved in Therapeutics Development

3SBio Inc

Bristol-Myers Squibb Co

KAHR medical Ltd

Momenta Pharmaceuticals Inc

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAHR-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Dormant Products

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Discontinued Products

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Product Development Milestones

Featured News & Press Releases

Feb 23, 2018: Orenzia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan

Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Nov 13, 2017: Bristol-Myers Squibb's Orenzia Rejects for Use within NHS Scotland

Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

Nov 01, 2017: Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)

Jul 26, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis

Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults

Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

Jun 08, 2017: Bristol-Myers Squibb Announces Availability of New ORENCIA

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipel...

(abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis

Mar 30, 2017: Supplemental Application of Orencia (Abatacept) Intravenous Injection 250 mg a Selective T-cell Co-stimulation Modulator for Treatment of Juvenile Idiopathic Arthritis for a Partial Change in Approved Items of Manufacturing and Marketing Approval

Mar 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland

Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)

Sep 06, 2016: European Commission Approves Bristol-Myers Squibb's ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 3SBio Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by KHR medical Ltd, H1 2018

Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

3SBio Inc

Bristol-Myers Squibb Co

KAHR medical Ltd

Momenta Pharmaceuticals Inc

I would like to order

Product name: T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/T5A19841EF9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T5A19841EF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

